StreetInsider.com News Articles

Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London

Mon, 08 Jun 2026 08:00:00 -0400

Rick Pierce to join speakers from Boehringer Ingelheim, RA Capital and ILiAD Biotechnologies for discussion on early clinical development

CAMBRIDGE, Mass., June 8, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families, today announced that Chief Executive Officer Rick Pierce will speak at the Capital Markets Day hosted by hVIVO plc (AIM: HVO) on June 11, 2026 in Canary Wharf, London.

Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London

Mon, 08 Jun 2026 08:00:00 -0400

Rick Pierce to join speakers from Boehringer Ingelheim, RA Capital and ILiAD Biotechnologies for discussion on early clinical development

Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London

Mon, 08 Jun 2026 08:00:00 -0400

Rick Pierce to join speakers from Boehringer Ingelheim, RA Capital and ILiAD Biotechnologies for discussion on early clinical development

Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London

Mon, 08 Jun 2026 08:00:00 -0400

Rick Pierce to join speakers from Boehringer Ingelheim, RA Capital and ILiAD Biotechnologies for discussion on early clinical development

Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London

Mon, 08 Jun 2026 08:00:00 -0400

Rick Pierce to join speakers from Boehringer Ingelheim, RA Capital and ILiAD Biotechnologies for discussion on early clinical development

Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London

Mon, 08 Jun 2026 08:00:00 -0400

Rick Pierce to join speakers from Boehringer Ingelheim, RA Capital and ILiAD Biotechnologies for discussion on early clinical development

Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London

Mon, 08 Jun 2026 08:00:00 -0400

Rick Pierce to join speakers from Boehringer Ingelheim, RA Capital and ILiAD Biotechnologies for discussion on early clinical development

Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London

Mon, 08 Jun 2026 08:00:00 -0400

Rick Pierce to join speakers from Boehringer Ingelheim, RA Capital and ILiAD Biotechnologies for discussion on early clinical development

Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London

Mon, 08 Jun 2026 08:00:00 -0400

Rick Pierce to join speakers from Boehringer Ingelheim, RA Capital and ILiAD Biotechnologies for discussion on early clinical development

Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London

Mon, 08 Jun 2026 08:00:00 -0400

Rick Pierce to join speakers from Boehringer Ingelheim, RA Capital and ILiAD Biotechnologies for discussion on early clinical development

Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London

Mon, 08 Jun 2026 08:00:00 -0400

Rick Pierce to join speakers from Boehringer Ingelheim, RA Capital and ILiAD Biotechnologies for discussion on early clinical development

Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London

Mon, 08 Jun 2026 08:00:00 -0400

Rick Pierce to join speakers from Boehringer Ingelheim, RA Capital and ILiAD Biotechnologies for discussion on early clinical development

Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London

Mon, 08 Jun 2026 08:00:00 -0400

Rick Pierce to join speakers from Boehringer Ingelheim, RA Capital and ILiAD Biotechnologies for discussion on early clinical development

Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London

Mon, 08 Jun 2026 08:00:00 -0400

Rick Pierce to join speakers from Boehringer Ingelheim, RA Capital and ILiAD Biotechnologies for discussion on early clinical development

Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic

Mon, 01 Jun 2026 07:00:00 -0400

Collaboration supports Phase 1 and Phase 2a human proof-of-concept studies for new antiviral category designed to address multiple viruses with a single adaptable therapeutic

CAMBRIDGE, Mass., June 1, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a pre-clinical-stage biotechnology company pioneering a new category of antivirals, today announced the execution of a strategic development initiative designed to support the advancement of the company's Designable Multi-Antiviral (D-MAV) candidates into Phase 1 first-in-human and Phase 2a human proof-of-concept studies.

Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic

Mon, 01 Jun 2026 07:00:00 -0400

Collaboration supports Phase 1 and Phase 2a human proof-of-concept studies for new antiviral category designed to address multiple viruses with a single adaptable therapeutic

Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic

Mon, 01 Jun 2026 07:00:00 -0400

Collaboration supports Phase 1 and Phase 2a human proof-of-concept studies for new antiviral category designed to address multiple viruses with a single adaptable therapeutic

Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic

Mon, 01 Jun 2026 07:00:00 -0400

Collaboration supports Phase 1 and Phase 2a human proof-of-concept studies for new antiviral category designed to address multiple viruses with a single adaptable therapeutic

Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic

Mon, 01 Jun 2026 07:00:00 -0400

Collaboration supports Phase 1 and Phase 2a human proof-of-concept studies for new antiviral category designed to address multiple viruses with a single adaptable therapeutic

Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic

Mon, 01 Jun 2026 07:00:00 -0400

Collaboration supports Phase 1 and Phase 2a human proof-of-concept studies for new antiviral category designed to address multiple viruses with a single adaptable therapeutic

Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic

Mon, 01 Jun 2026 07:00:00 -0400

Collaboration supports Phase 1 and Phase 2a human proof-of-concept studies for new antiviral category designed to address multiple viruses with a single adaptable therapeutic

Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic

Mon, 01 Jun 2026 07:00:00 -0400

Collaboration supports Phase 1 and Phase 2a human proof-of-concept studies for new antiviral category designed to address multiple viruses with a single adaptable therapeutic

Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic

Mon, 01 Jun 2026 07:00:00 -0400

Collaboration supports Phase 1 and Phase 2a human proof-of-concept studies for new antiviral category designed to address multiple viruses with a single adaptable therapeutic

Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic

Mon, 01 Jun 2026 07:00:00 -0400

Collaboration supports Phase 1 and Phase 2a human proof-of-concept studies for new antiviral category designed to address multiple viruses with a single adaptable therapeutic

Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic

Mon, 01 Jun 2026 07:00:00 -0400

Collaboration supports Phase 1 and Phase 2a human proof-of-concept studies for new antiviral category designed to address multiple viruses with a single adaptable therapeutic